BiVictriX Therapeutics PLC said it is in contact with several potential partner companies, signalling a growing interest in its recent advancements, including the development of its main asset, BVX001, targeting cancer.
In an interview with Proactive's Thomas Warner, Tiffany Thorne, the founder and CEO, highlighted the company's momentum.
"We're continually generating positive data for our lead programme and the wider platform. We're constantly in contact with some of these interested parties," Thorne said.
Supporting this interest is BiVictriX's recent accomplishment of securing US patent protection for BVX001.
This patent is particularly noteworthy due to its broader claims, distinguishing it from typical patents in the antibody therapeutic development sector.
Such expansive protection not only solidifies BiVictriX's position in the market but also offers the potential for groundbreaking advancements in therapeutic treatments.
For a comprehensive look into BiVictriX Therapeutics' recent developments and future aspirations, the full interview with Tiffany Thorne can be accessed on Proactive.